Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients
May Ee Png, Victoria Harris, Ly-Mee Yu, Paul Little et autres
Importance: Nirmatrelvir-ritonavir is an oral antiviral recommended for treating high-risk individuals with COVID-19 in the community. However, there remains uncertainty over its cost-effectiveness in largely vaccinated populations and subgroups defined by age and clinical risk. Objective: To compare the cost-effectiveness of nirmatrelvir-ritonavir …
gb, us (code pays fourni par la source)